Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
ESMO 2014 Highlights
CLEOPATRA: Record-Breaking Survival in HER2 Metastatic Breast Cancer by Adding Pertuzumab
By
Phoebe Starr
ESMO 2014 Highlights
,
ESMO
October 2014, Vol 5 , No 8
Madrid, Spain—Final results from the CLEOPATRA (Clinical Evaluation of Pertuzumab and Trastuzumab) trial show that dual HER2 blockade with the combination of pertuzumab and trastuzumab plus chemotherapy extended overall survival (OS) by almost 16 months compared with trastuzumab plus chemotherapy alone in patients with
HER2
-positive metastatic breast cancer.
Read Article
Mixed Results with Postprogression EGFR Inhibition in Advanced Non–Small-Cell Lung Cancer
By
Charles Bankhead
ESMO 2014 Highlights
,
ESMO
October 2014, Vol 5 , No 8
Madrid, Spain—Continuing an EGFR inhibitor after acquired resistance does not slow the progression of advanced non–small-cell lung cancer (NSCLC) in patients receiving chemotherapy, according to a report presented at the 2014 European Society for Medical Oncology (ESMO) Congress.
Read Article
New Data Show PFS, Survival Benefits with Bevacizumab in Breast Cancer
By
Charles Bankhead
ESMO 2014 Highlights
,
ESMO
October 2014, Vol 5 , No 8
Madrid, Spain—The positive results from 2 studies raised speculation about a possible resurrection of the breast cancer indication for bevacizumab, as reported at the 2014 European Society for Medical Oncology Congress.
Read Article
PD-1–Blocking Nivolumab Shows Impressive Responses in Melanoma
By
Phoebe Starr
ESMO 2014 Highlights
,
ESMO
October 2014, Vol 5 , No 8
Madrid, Spain—Immunotherapy marches on, showing continued progress in treating advanced melanoma. At the 2014 European Society for Medical Oncology (ESMO) Congress, first reports from a phase 3 clinical trial showed that the monoclonal anti–PD-1 antibody nivolumab achieved superior responses and longer progression-free survival (PFS) and overall survival (OS) compared with standard chemotherapy in the second- or third-line treatment of patients whose melanoma progressed with ipilimumab therapy.
Read Article
Record-Breaking Survival in HER2 Metastatic Breast Cancer by Adding Pertuzumab - Dual HER2 blockade a new standard of care
By
Phoebe Starr
ESMO 2014 Highlights
,
ESMO
October 2014, Vol 5 , No 8
>Madrid, Spain—Final results from the CLEOPATRA (Clinical Evaluation of Pertuzumab and Trastuzumab) trial show that dual
HER2
blockade with the combination of pertuzumab and trastuzumab plus chemotherapy extended overall survival (OS) by almost 16 months compared with trastuzumab plus chemotherapy alone in patients with
HER2
-positive metastatic breast cancer.
Read Article
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma